DrugCite
Search

HEMOFIL

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Hemofil Adverse Events Reported to the FDA Over Time

How are Hemofil adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Hemofil, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Hemofil is flagged as the suspect drug causing the adverse event.

Most Common Hemofil Adverse Events Reported to the FDA

What are the most common Hemofil adverse events reported to the FDA?

Adverse Event
1328 (5.57%)
Hiv Infection
498 (2.09%)
Drug Exposure During Pregnancy
409 (1.72%)
Hepatitis C
400 (1.68%)
Pyrexia
341 (1.43%)
Metal Poisoning
256 (1.07%)
Neurotoxicity
241 (1.01%)
Nausea
205 (.86%)
Dyspnoea
178 (.75%)
Hypoglycaemia
175 (.73%)
Vomiting
175 (.73%)
Show More Show More
Chills
173 (.73%)
Headache
173 (.73%)
Post Procedural Infection
169 (.71%)
Infection
155 (.65%)
Drug Ineffective
145 (.61%)
Neutropenia
145 (.61%)
Staphylococcal Infection
140 (.59%)
Infusion Related Reaction
123 (.52%)
Haemoglobin Decreased
121 (.51%)
Graft Infection
113 (.47%)
Convulsion
111 (.47%)
Blood Glucose Increased
109 (.46%)
Graft Complication
108 (.45%)
Hypotension
104 (.44%)
Erythema
99 (.42%)
Hypertension
98 (.41%)
Haemorrhage
97 (.41%)
Pneumonia
97 (.41%)
Diarrhoea
95 (.4%)
Sepsis
95 (.4%)
Post Procedural Complication
94 (.39%)
Arthralgia
92 (.39%)
Pain
91 (.38%)
Tachycardia
90 (.38%)
Renal Failure Acute
89 (.37%)
Rash
85 (.36%)
Transmission Of An Infectious Agent...
84 (.35%)
Condition Aggravated
83 (.35%)
Product Quality Issue
83 (.35%)
Pulmonary Oedema
81 (.34%)
Renal Failure
81 (.34%)
Loss Of Consciousness
80 (.34%)
Death
78 (.33%)
Thrombocytopenia
75 (.31%)
Tremor
75 (.31%)
Fatigue
74 (.31%)
Rash Maculo-papular
74 (.31%)
Asthenia
72 (.3%)
Dizziness
72 (.3%)
Hypersensitivity
72 (.3%)
Multi-organ Failure
72 (.3%)
Hepatitis B
70 (.29%)
Malaise
70 (.29%)
Chest Pain
69 (.29%)
Acquired Immunodeficiency Syndrome
68 (.29%)
Rash Erythematous
68 (.29%)
Respiratory Failure
68 (.29%)
Blood Pressure Increased
67 (.28%)
Factor Viii Inhibition
67 (.28%)
Postoperative Wound Infection
67 (.28%)
Melaena
65 (.27%)
Pruritus
65 (.27%)
Purpura
65 (.27%)
Hyperhidrosis
64 (.27%)
Pulmonary Embolism
64 (.27%)
Rectal Haemorrhage
64 (.27%)
Anaphylactic Reaction
63 (.26%)
Blood Pressure Decreased
62 (.26%)
Cerebrovascular Accident
62 (.26%)
Blood Glucose Decreased
61 (.26%)
Drug Interaction
61 (.26%)
Anaemia
60 (.25%)
Cardiac Arrest
60 (.25%)
Vaginal Haemorrhage
60 (.25%)
Fall
59 (.25%)
General Physical Health Deteriorati...
59 (.25%)
Heart Rate Increased
56 (.23%)
Poor Quality Drug Administered
56 (.23%)
Pseudomonas Infection
56 (.23%)
Depressed Level Of Consciousness
55 (.23%)
Oxygen Saturation Decreased
55 (.23%)
Abortion Spontaneous
53 (.22%)
Oedema Peripheral
53 (.22%)
Urinary Tract Infection
53 (.22%)
Urticaria
52 (.22%)
Abdominal Pain
51 (.21%)
Feeling Abnormal
51 (.21%)
Myocardial Infarction
50 (.21%)
Premature Baby
50 (.21%)
Aspartate Aminotransferase Increase...
49 (.21%)
Confusional State
49 (.21%)
Medication Error
49 (.21%)
Swelling
49 (.21%)
Caesarean Section
48 (.2%)
Haemolysis
48 (.2%)
Wound Dehiscence
47 (.2%)
Cardiac Failure
46 (.19%)
Coma
46 (.19%)
Impaired Healing
46 (.19%)
Complications Of Transplant Surgery
45 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Hemofil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Hemofil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Hemofil

What are the most common Hemofil adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Hemofil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Hemofil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Hemofil According to Those Reporting Adverse Events

Why are people taking Hemofil, according to those reporting adverse events to the FDA?

Haemophilia
1908
Diabetes Mellitus
1013
Drug Use For Unknown Indication
743
Product Used For Unknown Indication
516
Idiopathic Thrombocytopenic Purpura
441
Factor Viii Deficiency
329
Show More Show More
Soft Tissue Disorder
270
Type 2 Diabetes Mellitus
245
Hypoalbuminaemia
177
Diabetes Mellitus Insulin-dependent
141
Off Label Use
138
Prophylaxis
113
Surgery
93
Kawasakis Disease
92
Diabetes Mellitus Non-insulin-depen...
84
Glycogen Storage Disease Type Ii
83
Type 1 Diabetes Mellitus
79
Hypogammaglobulinaemia
79
Immunodeficiency Common Variable
76
Pregnancy
66
Infection Prophylaxis
65
Therapeutic Procedure
65
Anaemia
61
Ill-defined Disorder
54
Chronic Inflammatory Demyelinating ...
54
Guillain-barre Syndrome
53
Thrombocytopenia
50
Insulin-requiring Type Ii Diabetes ...
50
Hepatic Cirrhosis
41
Demyelinating Polyneuropathy
40
Aplastic Anaemia
38
Systemic Lupus Erythematosus
35
Immunodeficiency
34
Evans Syndrome
34
Hyperglycaemia
33
Corneal Dystrophy
33
Multiple Sclerosis
32
Primary Immunodeficiency Syndrome
30
Ascites
30
Myasthenia Gravis
29
Accidental Exposure
29
Transplant
28
Hypoproteinaemia
28
Histiocytosis Haematophagic
27
Haemorrhage
27
Infection
25
Infertility
24
Blood Albumin Decreased
24
Ligament Operation
24
Fluid Replacement
23
Factor Ix Deficiency
23

Drug Labels

LabelLabelerEffective
Hemofil MBaxter Healthcare Corporation20-APR-12

Hemofil Case Reports

What Hemofil safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Hemofil. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Hemofil.